HeartBeam has received US Food and Drug Administration (FDA) 510(k) clearance for its synthesized 12-lead electrocardiogram (ECG) software.
This decision follows a successful appeal of an earlier Not Substantially Equivalent (NSE) determination. The clearance marks a significant milestone for the company, allowing it to proceed with its strategy to commercialize a portable device designed for arrhythmia assessment outside clinical settings.
Following the news, the California-based company’s stock shot up by 93.75% at market close on 10 December, compared to the market close on the previous day.
Technology Enables Clinical-Grade Insights at Home
The core of HeartBeam’s innovation is a patented method that captures the heart’s electrical signals in three dimensions using a cable-free device. This data is then synthesized into a visual 12-lead ECG representation, similar to those produced by standard diagnostic machines in medical facilities.
Unlike consumer single-lead or 6-lead devices, this approach aims to provide a more comprehensive view, enabling patients to capture readings during symptomatic moments at home, as per the company. The synthesized ECG is subsequently reviewed by a board-certified cardiologist on-demand.
The FDA clearance specifies that the system is for recording, storing, and transferring ECG data for manual physician interpretation. It is cleared only for assessing normal sinus rhythm and a specific set of non-life-threatening arrhythmias. The company explicitly notes the software is not intended to replace a standard 12-lead ECG or for the assessment of life-threatening conditions like myocardial infarction.
With regulatory approval secured, HeartBeam outlined several key initiatives. The company plans a limited US commercial launch in the first quarter of 2026, initially targeting concierge and preventive cardiology groups. This phased approach is intended to validate real-world performance. Future efforts will focus on pursuing a heart attack detection indication, advancing an extended-wear patch version of the technology, and leveraging longitudinal patient data to develop AI-based screening algorithms.
Company CEO Robert Eno described the FDA clearance as a “defining moment” and the true start of HeartBeam’s mission to revolutionize cardiac care. He emphasized the importance of the FDA’s collaborative review process.
Dr. Robert A. Harrington, a cardiologist and scientific advisor to HeartBeam, highlighted the clinical need the device addresses, noting that cardiac symptoms often occur unpredictably outside a doctor’s office. The ability to capture meaningful data immediately, he stated, can lead to clearer diagnoses and more timely interventions.
